重组人sTNF RII/TNFRSF1B,Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B 生命科学产品与技术服务-生工生物工程(上海)股份有限公司

Order NO. C600337

重组人sTNF RII/TNFRSF1B

英文名	Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B
别名	sTNF RII/TNFRSF1B, Human
相关类别	其他重组蛋白	储存	冷冻（-20℃）
分子量	Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids.
在线咨询

编号	包装	库存	目录价（￥）	您的价格（￥）	数量
C600337-0005	5 UG	预计20日内发货			暂不支持线上订购

产品描述

概述

Tumor Necrosis Factor Receptor-I (TNF RI, also known as p55/p60) and TNF RII (also known as p75/p80) are both high affinity receptors for TNF-alpha and -beta, potent mediators of multiple aspects of inflammatory immune responses. Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Whereas all cell types are thought to express TNF RI, TNF RII expression is limited primarily to hematopoietic cells and cells of the immune system. Most of the biological functions of TNF are mediated via TNF RI. Soluble forms of both TNF RI and TNF RII, generated as a result of proteolytic cleavage of the extracellular domains, have been detected in vivo in various biological fluids. The soluble TNF receptors can bind TNF with high affinity and functions as TNF antagonists.

使用说明

This material is offered by Sangon Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

属性

Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Purity	> 97 % by SDS-PAGE and HPLC analyses.
Source	Escherichia coli.
Biological Activity	Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 μg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.
Endotoxin	Less than 0.1 EU/μg of rHusTNF RII/TNFRSF1B as determined by LAL method.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
AA Sequence	MPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPT